Thomas Steyer’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Thomas Steyer’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,250,000	Closed	-$31.4M	–	133
2020 Q1	$31.4M	Hold	8,250,000	–	–	0.27%	54
2019 Q4	$42M	Buy	8,250,000 +900,000	+12%	+$4.76M	0.28%	61
2019 Q3	$37.2M	Buy	7,350,000 +1,806,614	+33%	+$9.01M	0.28%	53
2019 Q2	$34.2M	Buy	5,543,386 +1,342,566	+32%	+$6.47M	0.22%	63
2019 Q1	$19.5M	Hold	4,200,820	–	–	0.15%	73
2018 Q4	$17.6M	Buy	4,200,820 +588,000	+16%	+$2.99M	0.13%	71
2018 Q3	$22.7M	Buy	3,612,820 +961,720	+36%	+$7.39M	0.13%	63
2018 Q2	$21.3M	Buy	+2,651,100	New	+$20.2M	0.13%	63

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Thomas Steyer's PGNX Position: Q2 2020 in Review

Thomas Steyer sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 8,250,000 shares — an estimated $31.4M sold.

Thomas Steyer first reported a position in PGNX in Q2 2018 and held it in 8 quarters. The position peaked at $42M in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Thomas Steyer reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Thomas Steyer sold 8,250,000 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $31.4M.
Thomas Steyer first reported a position in Progenics Pharmaceuticals Inc in Q2 2018 and held it in 8 quarters.
Thomas Steyer's Progenics Pharmaceuticals Inc position peaked at $42M in Q4 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.